Jasper Therapeutics, Inc.

NasdaqCM:JSPR Stock Report

Market Cap: US$90.9m

Jasper Therapeutics Management

Management criteria checks 2/4

Jasper Therapeutics' CEO is Ron Martell, appointed in Mar 2022, has a tenure of 2.92 years. total yearly compensation is $3.37M, comprised of 20.6% salary and 79.4% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth $200.70K. The average tenure of the management team and the board of directors is 2.1 years and 2.5 years respectively.

Key information

Ron Martell

Chief executive officer

US$3.4m

Total compensation

CEO salary percentage20.6%
CEO tenure2.9yrs
CEO ownership0.2%
Management average tenure2.1yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jan 04
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Deliver On Growth Plans?

Jasper Therapeutics: Briquilimab's Potential In Chronic Urticaria And Asthma

Nov 18

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Aug 30
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Jan 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Needs To Drive Business Growth Carefully

Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

Jul 31
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Are In A Position To Invest In Growth

We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Feb 02
We're Keeping An Eye On Jasper Therapeutics' (NASDAQ:JSPR) Cash Burn Rate

Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Oct 14
Jasper Therapeutics (NASDAQ:JSPR) Will Have To Spend Its Cash Wisely

Jasper Therapeutics GAAP EPS of -$0.29 beats by $0.02

Aug 12

Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jun 19
Is Jasper Therapeutics (NASDAQ:JSPR) In A Good Position To Invest In Growth?

Jasper Therapeutics: Advancing Cures With HSC Transplants And Safer Prior Conditioning

Nov 28

We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

Nov 23
We Think Jasper Therapeutics (NASDAQ:JSPR) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Ron Martell's remuneration changed compared to Jasper Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$64m

Jun 30 2024n/an/a

-US$62m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$3mUS$695k

-US$64m

Sep 30 2023n/an/a

-US$61m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$6mUS$510k

-US$38m

Compensation vs Market: Ron's total compensation ($USD3.37M) is above average for companies of similar size in the US market ($USD640.24K).

Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.

CEO

Ron Martell (62 yo)

2.9yrs

Tenure

US$3,369,990

Compensation

Mr. Ronald A. Martell, also known as Ron, serves as President, Chief Executive Officer & Director at Jasper Therapeutics, Inc. since March 15, 2022. He has been Chief Financial Officer and Director at Morp...

Leadership Team

NamePositionTenureCompensationOwnership
Ronald Martell
President2.9yrsUS$3.37m0.22%
$ 200.7k
Judith Shizuru
Co-Founder & Directorno dataUS$357.71k0.77%
$ 702.4k
Jeetinder Mahal
Chief Operating Officer2.9yrsUS$1.18m0.17%
$ 151.6k
Edwin Tucker
Chief Medical Officer1.7yrsUS$977.73k0.0027%
$ 2.4k
Herbert Cross
CFO & Corporate Secretary1.4yrsno datano data
David Ku
Vice President of Corporate Developmentno datano datano data
Matthew Ford
Vice President of Human Resources2.1yrsno datano data
Wendy Pang
Senior Vice President of Research & Translational Medicine2.9yrsno datano data
Luca Di Noto
Senior Vice President of Technical Operationsno datano datano data
Patricia Carlos
Senior Vice President of Regulatory Affairs & Quality1.5yrsno datano data

2.1yrs

Average Tenure

52yo

Average Age

Experienced Management: JSPR's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ronald Martell
President2.9yrsUS$3.37m0.22%
$ 200.7k
Judith Shizuru
Co-Founder & Director6.9yrsUS$357.71k0.77%
$ 702.4k
Thomas Wiggans
Independent Chairman1.3yrsUS$76.47k0.033%
$ 30.3k
Kurt von Emster
Independent Director5.3yrsUS$128.21k0.014%
$ 12.8k
Daniel Adelman
Member of Scientific Advisory Board & Senior Clinical Advisor1.7yrsno datano data
Arthur Weiss
Member of Scientific Advisory Boardno datano datano data
Frederick Appelbaum
Member of Scientific Advisory Boardno datano datano data
Jeffrey Ravetch
Member of Scientific Advisory Boardno datano datano data
Stephen Galli
Member of Scientific Advisory Board1.8yrsno datano data
Vishal Kapoor
Independent Director2yrsUS$266.47k0.029%
$ 26.5k
Harry Malech
Member of Scientific Advisory Boardno datano datano data
Christian Nolet
Independent Director3.4yrsUS$126.41k0.022%
$ 19.7k

2.5yrs

Average Tenure

67yo

Average Age

Experienced Board: JSPR's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 21:14
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jasper Therapeutics, Inc. is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Etzer DaroutBMO Capital Markets Equity Research
Matthew LuchiniBMO Capital Markets Equity Research
Justin ZelinBTIG